Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Mol Cancer Ther. 2021 Aug 19;20(11):2166–2176. doi: 10.1158/1535-7163.MCT-20-0652

Figure 2. Pyrvinium Pamoate Inhibits Mitochondrial Oxidative Phosphorylation:

Figure 2

A) Treatment of MIA-PaCa2 cells with mitotracker (green) and PP (red) for one hour displayed co-localization of these two agents B,C,D) Cells were pretreated with either PP .3uM or vehicle for 12 hours prior to analysis of cellular Oxygen Consumption Rate B) which was used to quantify total, mitochondrial and Non-mitochondrial OCR (C) and concomitant ECAR measurements were also taken (D) E,F) Cells were treated with PP .3uM and OCR and ECAR were measured over time (n=1) G) Cells were treated with PP .3uM +/− glucose (25mM), gemcitabine (negative control) (no glucose), or vehicle and then ATP levels were determined (n=3) H) Cell treated with PP (.3μM) without glucose experience a decrease in ATP prior to a decrease in viability (n=3) I) In regular glucose conditions PP inhibits mitochondrial ATP production, however, cells can increase glycolysis leading to a protection from acute ATP loss. Contrastingly, in low glucose cells cannot rescue ATP production leading to necrosis.